{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:07:53Z","timestamp":1775275673822,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00270-024-03699-9","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T18:02:14Z","timestamp":1712167334000},"page":"567-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant in Situ and Systemic Immunotherapy with Lymph Node Cryoablation in Resectable Stage III Melanoma Metastasis: a Proof-of-Concept Study"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5207-3357","authenticated-orcid":false,"given":"Antoine","family":"Braud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Auloge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Bouvrais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mousselim","family":"Gharbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin","family":"Gangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Lipsker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"3699_CR1","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.annonc.2020.07.005","volume":"31","author":"O Michielin","year":"2020","unstructured":"Michielin O, van Akkooi A, Lorigan P, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO guidelines committee. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:1449\u201361. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.005.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"3699_CR2","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709030.","journal-title":"N Engl J Med"},{"key":"3699_CR3","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1708539.","journal-title":"N Engl J Med"},{"key":"3699_CR4","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1613210.","journal-title":"N Engl J Med"},{"key":"3699_CR5","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.jvir.2021.07.002","volume":"32","author":"P-A Autrusseau","year":"2021","unstructured":"Autrusseau P-A, Cazzato RL, Koch G, et al. Freezing nodal disease: local control following percutaneous image-guided cryoablation of locoregional and distant lymph node oligometastases: a 10-year. Single-Center Exp J Vasc Interv Radiol. 2021;32:1435\u201344. https:\/\/doi.org\/10.1016\/j.jvir.2021.07.002.","journal-title":"Single-Center Exp J Vasc Interv Radiol"},{"key":"3699_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fonc.2018.00085","volume":"8","author":"J Abdo","year":"2018","unstructured":"Abdo J, Cornell DL, Mittal SK, et al. Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers. Front Oncol. 2018;8:85. https:\/\/doi.org\/10.3389\/fonc.2018.00085.","journal-title":"Front Oncol"},{"key":"3699_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24:1655\u201361. https:\/\/doi.org\/10.1038\/s41591-018-0198-0.","journal-title":"Nat Med"},{"key":"3699_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bja.2020.04.092","volume":"125","author":"D Ferreira","year":"2020","unstructured":"Ferreira D, Barthoulot M, Pottecher J, et al. Theory and practical use of Bayesian methods in interpreting clinical trial data: a narrative review. Br J Anaesth. 2020;125:201\u20137. https:\/\/doi.org\/10.1016\/j.bja.2020.04.092.","journal-title":"Br J Anaesth"},{"key":"3699_CR9","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.1002\/cncr.24628","volume":"115","author":"M Adamina","year":"2009","unstructured":"Adamina M, Tomlinson G, Guller U. Bayesian statistics in oncology: a guide for the clinical investigator. Cancer. 2009;115:5371\u201381. https:\/\/doi.org\/10.1002\/cncr.24628.","journal-title":"Cancer"},{"key":"3699_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/pst.185","volume":"4","author":"SA Julious","year":"2005","unstructured":"Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4:287\u201391. https:\/\/doi.org\/10.1002\/pst.185.","journal-title":"Pharm Stat"},{"key":"3699_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00081-4","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont AMM, Blank CU, Mandal\u00e0 M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:643\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(21)00081-4.","journal-title":"Lancet Oncol"},{"key":"3699_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejca.2022.06.041","volume":"173","author":"J Larkin","year":"2022","unstructured":"Larkin J, Weber J, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. Eur J Cancer Oxf Engl. 2022;173:285\u201396. https:\/\/doi.org\/10.1016\/j.ejca.2022.06.041.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"3699_CR13","doi-asserted-by":"publisher","first-page":"9501","DOI":"10.1200\/JCO.2022.40.16_suppl.9501","volume":"40","author":"CU Blank","year":"2022","unstructured":"Blank CU, Reijers ILM, Saw RPM, et al. Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol. 2022;40:9501\u20139501. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9501.","journal-title":"J Clin Oncol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-024-03699-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T16:03:15Z","timestamp":1715011395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-024-03699-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["3699"],"URL":"https:\/\/doi.org\/10.1007\/s00270-024-03699-9","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"29 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}